HSC Section 6 Nov2016 Green Book

drafting of the manuscript, critical revision of the manuscript for important intellectual content: Fouad J. Moawad; study concept and design, study enrollment, acquisition of data, analysis and inter- pretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content: Ganesh R. Veerappan; data collection, verification and analysis, drafting of the manuscript: Johnny A. Dias; histological analysis, drafting of the manuscript: Thomas P. Baker; study concept and design, analysis and interpreta- tion of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content: Corinne L. Maydonovitch; study concept and design, drafting of the manuscript, critical revision of the manuscript for important intellectual Disclaimer The opinions are solely those of the authors and do not represent an endorsement by the Department of Defense. This is US Government work. There are no restrictions on its use. Study Highlights WHAT IS CURRENT KNOWLEDGE 3 Topical steroids are commonly used as first line treatment for patients with a clinical presentation suggestive of EoE and who have dense eosinophilic infiltration. 3 PPI therapy is often prescribed in esophageal eosinophilia patients to help treat coexisting GERD and establish diagnosis of EoE. WHAT IS NEW HERE 3 Topical fluticasone had a lower than expected response rate which may be dose and delivery related. 3 PPIs induce histological response in some patients with eso- phageal eosinophilia regardless of the presence of GERD. 3 PPIs significantly improved clinical symptoms in patients with esophageal eosinophilia even in the absence of GERD. REFERENCES 1. Moawad FJ, Veerappan GR, Wong RK. Eosinophilic esophagitis. Dig Dis Sci 2009;54:1818–28. 2. Liacouras CA, Furuta GT, Hirano I et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128:3–20. 3. Furuta GT, Liacouras CA, Collins MH et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:1342–63. 4. Ngo P , Furuta GT, Antonioli DA et al. Eosinophils in the esophagus- peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol 2006;101:1666–70. 5. Desai TK, Stecevic V , Chang CH et al. Association of eosinophilic inflammation with esophageal food impaction in adults. Gastrointest Endosc 2005;61:795–801. 6. Hirano I. Eosinophilic esophagitis and gastroesophageal reflux disease: there and back again. Clin Gastroenterol Hepatol 2011;9:99–101. content: Roy K.H. Wong. Financial support: None. Potential competing interests : None.

7. Grudell AB, Alexander JA, Enders FB et al. Validation of the Mayo Dysphagia Questionnaire. Dis Esophagus 2007;20:202–5. 8. Johnson LF, Demeester TR. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974;62:325–32. 9. Johnson LF, DeMeester TR. Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol 1986;8 (Suppl 1): 52–8. 10. Noel RJ, Putnam PE, Collins MH et al. Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastro- enterol Hepatol 2004;2:568–75. 11. Konikoff MR, Noel RJ, Blanchard C et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131:1381–91. 12. Schaefer ET, Fitzgerald JF, Molleston JP et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008;6:165–73. 13. Peterson KA, Thomas KL, Hilden K et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 2010;55:1313–9. 14. Alexander JA, Jung KW , Arora AS et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic eso- phagitis. Clin Gastroenterol Hepatol 2012;10:742–9. 15. Sperry SL, Shaheen NJ, Dellon ES. Toward uniformity in the diagnosis of eosinophilic esophagitis (EoE): the effect of guidelines on variability of diagnostic criteria for EoE. Am J Gastroenterol 2011; 106:824–32. 16. Straumann A, Conus S, Degen L et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010;139:1526–37. 17. Straumann A, Conus S, Degen L et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011;9:400–9. 18. Aceves SS, Bastian JF, Newbury RO et al. Oral viscous budesonide: a poten- tial new therapy for eosinophilic esophagitis in children. Am J Gastroen- terol 2007;102:2271–9. 19. Dellon ES, Sheikh A, Speck O et al. Viscous Topical Is More Effective Than Nebulized Steroid Therapy for Patients With Eosinophilic Esophagitis. Gastroenterology 2012;143:321–4. 20. Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol 2007;102:1301–6. 21. Cortes JR, Rivas MD, Molina-Infante J et al. Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma. J Allergy Clin Immunol 2009;124:607–10. 22. Zhang X CE, Hou X et al. In esophageal epithelial cell lines from patients with eosinophilic esophagitis (EoE), omeprazole blocks the stimulated secretion of eotaxin-3: a potential anti-inflammatory effect of omeprazole in EoE that is independent of acid inhibition. Gastroenterology 2010;138 (suppl 1): S–122. 23. Dranove JE, Horn DS, Davis MA et al. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosi- nophilia. J Pediatr 2009;154:96–100. 24. Molina-Infante J, Ferrando-Lamana L, Ripoll C et al. Esophageal eosi- nophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol 2011;9:110–7. 25. Pentiuk S, Putnam PE, Collins MH et al. Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009;48:152–60. 26. Schoepfer AM, Gonsalves N, Bussmann C et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol 2010;105:1062–70. 27. Straumann A, Spichtin HP , Grize L et al. Natural history of primary eosi- nophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003;125:1660–9.

The American Journal of GASTROENTEROLOGY

125